SciBase Holding AB (SciBase) (STO:SCIB), a developer of augmented intelligence-based solutions for skin disorders, revealed on Wednesday that it has entered into a collaboration agreement with Schweiger Dermatology group (SDG) to pilot the Nevisense skin cancer detection test at SDG's Freehold, NJ office.
Nevisense is reportedly the only FDA approved test for early melanoma detection at point-of-care.
According to SciBase, SDG is the largest dermatology practice group in the Northeastern US, with over 90 offices and more than 300 healthcare providers throughout New York, New Jersey, Pennsylvania and Connecticut.
Simon Grant, CEO of SciBase, stated: "We are very pleased to announce our collaboration with Schweiger Dermatology Group. In addition to the early detection benefits for patients, the partnership means clinicians at Schweiger Dermatology Group's Freehold and Verona, New Jersey offices will have access to state-of-the-art melanoma detection technology. For SciBase, we establish a further partner that helps introduce Nevisense to US payers."
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT